United States securities and exchange commission logo





                              September 29, 2022

       Richard Garr
       Chief Executive Officer
       Curative Biotechnology, Inc.
       1825 NW Corporate Blvd, Suite 110
       Boca Raton, FL 33431

                                                        Re: Curative
Biotechnology, Inc.
                                                            Amendment No. 8 to
Registration Statement on Form S-1
                                                            Filed September 28,
2022
                                                            File No. 333-264339

       Dear Mr. Garr:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 8 to Registration Statement on Form S-1 filed September
28, 2022

       Description of Securities, page 56

   1.                                                   We note your disclosure
that Aegis Capital Corp. will receive Underwriter's Warrants in
                                                        connection with the
offering. Please revise to provide a description of the warrants in the
                                                        offering. Please refer
to Item 202 of Regulation S-K.
       General

   2.                                                   Please have counsel
revise its opinion to include the shares which may be issued pursuant
                                                        to the underwriter's
overallotment option. We also note that twice you refer to "the
                                                        Shares." Please revise
as this is not a defined term.
 Richard Garr
FirstName LastNameRichard
Curative Biotechnology, Inc. Garr
Comapany 29,
September  NameCurative
               2022      Biotechnology, Inc.
September
Page 2     29, 2022 Page 2
FirstName LastName
3.       We note you included the last reported sales price for your common
stock as quoted on
         the OTC Pink was $0.03 per share as of September 14, 2022. Please
revise this figure to
         provide such information as of a more recent date.
        You may contact Jeanne Bennett at 202-551-3606 or Vanessa Robertson at
202-551-3649
if you have questions regarding comments on the financial statements and
related
matters. Please contact Jason Drory at 202-551-8342 or Margaret Schwartz at
202-551-7153
with any other questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:      Raul Silvestre, Esq.